News Sentiment

LSTA sentiment intelligence

Lisata Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.27 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

72/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-1.8% over one week, -8.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered

Market Reaction

Balanced read

56/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 72/100 classification
One-week reaction -1.8% Price digesting
Trend fit Trend inactive -8.1% over four weeks
Fair value 13.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 31
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 6
TradingView 6
TradingKey 5
GlobeNewswire 4
Finviz 2
simplywall.st 2
dars.gov.et 1

Event Lens

What the news is about

Classified themes
Earnings 15
Deals and strategy 15
Market update 13
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
Stock Titan Direct company coverage

Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered

Kuva Acquisition Corp. has extended its tender offer for Lisata Therapeutics (LSTA) shares to July 16, 2026, with the offer price remaining at $4.00 cash per share plus one contingent value right (CVR) for potential additional payments up to $3.00. Over 5.1 million shares, repres

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 21:09
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA

This article provides the "Price to sales forward" value for Lisata Therapeutics, Inc. (NASDAQ: LSTA). It presents the company's stock information, including its ticker symbol, exchange, and market status. Although the specific financial value is not displayed, the article focuse

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 16:41
Source
TradingView
Stock Titan Direct company coverage

Lisata Therapeutics (LSTA) amends 14D-9, restates $4.00 cash offer plus CVR

Lisata Therapeutics has amended its Schedule 14D-9 filing to provide additional disclosures regarding the proposed tender offer by Kuva Acquisition Corp. The amendment clarifies board deliberations, an alternative offer, fairness analyses, and includes details about six demand le

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 20:10
Source
Stock Titan
Finviz Direct company coverage

LSTA - Lisata Therapeutics Inc Website Traffic and Mobile Apps Usage

This article provides a detailed financial and news overview of Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It includes stock performance data, key financial metrics, insider and institutional ownership, and a comprehensive list of corporate news rele

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 10:10
Source
Finviz
TradingView Direct company coverage

Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE)

This article provides current financial actuals and estimates for Lisata Therapeutics, Inc. (DUS:8NE), including income statement, balance sheet, and cash flow data. It also covers stock performance details like all-time high/lows, upcoming earnings dates, net income, EBITDA, and

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

LSTA Forecast — Price Target — Prediction for 2027

This article provides financial information and forecasts for Lisata Therapeutics, Inc. (LSTA), including its stock ticker, historical prices, earnings reports, net income, EBITDA, and employee count. It also addresses frequently asked questions about buying LSTA shares and confi

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:11
Source
TradingView
GlobeNewswire Direct company coverage

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (LSTA) on behalf of investors who suffered losses due to disclosures regarding the financing of its proposed acquisition by Kuva Labs, Inc. The investigation follows multiple amendments and delays in the tender offer

Tone
Negative 28/100
Event
Deals and strategy
Published
26 Jun 2026 15:11
Source
GlobeNewswire
TradingView Direct company coverage

Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA)

This article provides an overview of Lisata Therapeutics, Inc. (NASDAQ: LSTA), covering its current stock price, historical performance, market capitalization, and financial estimates. It highlights key financial data like net income and EBITDA, upcoming earnings dates, and addre

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:11
Source
TradingView
TradingKey Direct company coverage

Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lisata Therapeutics Inc (LSTA), highlighting its price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. As of June 24, 2026, LSTA has a price momentum score of 7.10, wi

Tone
Negative 36/100
Event
Market update
Published
25 Jun 2026 00:09
Source
TradingKey
Simply Wall Street Direct company coverage

LSTA: Kuva Tender Offer Uncertainty Will Ultimately Support Future Upside Potential

Analyst price targets for Lisata Therapeutics have been reduced to $4.00, reflecting increased uncertainty surrounding the proposed Kuva Labs acquisition. Under the tender offer, Lisata shareholders are offered $4.00 cash per share plus a contingent value right (CVR) that could p

Tone
Negative 36/100
Event
Deals and strategy
Published
23 Jun 2026 12:10
Source
Simply Wall Street
TradingKey Direct company coverage

Lisata Therapeutics Inc (LSTA) Institutional Confidence

Lisata Therapeutics Inc (LSTA) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 34.03% quarter-over-quarter to 10.92%. James Simons is the largest inst

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

Lisata Therapeutics Inc (LSTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lisata Therapeutics Inc (LSTA) has an earnings forecast score of 7.33, ranking 295 out of 388 in its industry. Analysts have set an average price target of $15.00 for LSTA, with a high of $15.00 and a low of $9.00, and predominantly recommend a "Buy" rating for the stock. This an

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 19:41
Source
TradingKey
TradingKey Direct company coverage

Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Lisata Therapeutics Inc (LSTA), including its business segments, regional revenue, and profit contribution. It notes that relevant financial data for these categories have not yet been disclosed by the company. The page provides a ge

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 15:40
Source
TradingKey
TradingKey Direct company coverage

Lisata Therapeutics Inc (LSTA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lisata Therapeutics Inc (LSTA) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and details a 15-to-1 merger-related stock split that occurred on Septembe

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 15:40
Source
TradingKey
TMX Newsfile Direct company coverage

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

Brodsky & Smith is investigating potential claims against Lisata Therapeutics, Inc. (LSTA) regarding its sale to Kuva Labs, Inc. for $4.00 per share cash plus two contingent value rights. The investigation focuses on whether Lisata's Board of Directors breached fiduciary duties b

Tone
Negative 28/100
Event
Regulatory and legal
Published
15 Jun 2026 21:09
Source
TMX Newsfile
Moomoo Direct company coverage

Press Release: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata Therapeutics has announced the commencement of a cash tender offer by Kuva Labs Inc., facilitated through its wholly-owned subsidiary, Kuva Merger Sub Inc. This offer is for all outstanding shares of Lisata's common stock at an acquisition price of $0.90 per share. The ten

Tone
Positive 67/100
Event
Deals and strategy
Published
11 Jun 2026 08:39
Source
Moomoo
Proactive financial news Direct company coverage

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right up to an additional $3.00 per share tied to drug development milestones. The tender offer launched on June 10, with the offer period set to expir

Tone
Positive 67/100
Event
Balance sheet
Published
11 Jun 2026 07:40
Source
Proactive financial news
GlobeNewswire Direct company coverage

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata Therapeutics announced that Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., has commenced a tender offer to acquire all outstanding shares of Lisata common stock. Stockholders will receive $4.00 per share in cash plus one non-tradeable contingent value right (CVR)

Tone
Positive 71/100
Event
Deals and strategy
Published
10 Jun 2026 18:09
Source
GlobeNewswire
Stock Titan Direct company coverage

[SC TO-T] LISATA THERAPEUTICS, INC. Third-Party Tender Offer | LSTA SEC Filing - Form SC TO-T

This SEC filing (Form SC TO-T) details a third-party tender offer by Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., to purchase all outstanding common shares of Lisata Therapeutics, Inc. for $4.00 per share in cash plus one contingent value right (CVR) that could yield a

Tone
Positive 72/100
Event
Deals and strategy
Published
10 Jun 2026 11:39
Source
Stock Titan
Stock Titan Direct company coverage

[SC 14D9] LISATA THERAPEUTICS, INC. Tender Offer Recommendation

Lisata Therapeutics, Inc. (LSTA) has filed an SC 14D9 recommending shareholders accept a tender offer from Kuva Acquisition Corp., a wholly-owned subsidiary of Kuva Labs Inc. The offer comprises $4.00 per common share in cash upfront, plus one non-tradeable contingent value right

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jun 2026 08:39
Source
Stock Titan
Stock Titan Direct company coverage

LSTA SEC Filings - Lisata Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page on StockTitan provides a comprehensive resource for investors to access official regulatory documents for Lisata Therapeutics (LSTA), including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Recent filings detail events such as a non-exclusive AD

Tone
Positive 65/100
Event
Earnings
Published
10 Jun 2026 04:39
Source
Stock Titan
Stock Titan Direct company coverage

Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee

Lisata Therapeutics and Kuva Labs have amended their merger agreement, extending the tender offer commencement deadline to June 10, 2026, and the transaction "Outside Date" to July 17, 2026, with an option for further extension to August 17, 2026, for a $1.5 million fee. Lisata a

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jun 2026 11:10
Source
Stock Titan
TradingView Direct company coverage

Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17

Lisata Therapeutics has extended its merger agreement with Kuva Labs by signing an Amendment and Waiver. This adjustment moves the "Outside Date" to July 17, 2026, with a further option to extend to August 17, 2026, for a $1.5 million payment, aiming to navigate financing uncerta

Tone
Negative 38/100
Event
Deals and strategy
Published
09 Jun 2026 11:10
Source
TradingView
Finviz Direct company coverage

LSTA - Lisata Therapeutics Inc Stock Price and Quote

This article provides a detailed stock quote and financial data for Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It lists key financial metrics, stock performance indicators, and recent news headlines including acquisition efforts by Kuva Labs and vari

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jun 2026 05:11
Source
Finviz